Company news
Celltrion, Inc. (KRX:068270) news
Celltrion, Inc. news releases on 6ix. Latest, Jul 27, 2026: Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record…
Press releases & updates
Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
July 26, 2026
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
April 21, 2026
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
March 16, 2026
Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
November 30, 2025
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
November 26, 2025
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
November 2, 2025
U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
October 30, 2025
FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
October 17, 2025
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
October 9, 2025
Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
October 2, 2025
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
August 6, 2025
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
July 6, 2025
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
June 15, 2025
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
May 23, 2025
Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
April 28, 2025
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
March 27, 2025
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
March 12, 2025
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
March 9, 2025
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
March 2, 2025
U.S. FDA approves Celltrion's AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
January 29, 2025
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant
January 3, 2022
Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
January 13, 2021